Investors

Company Profile

Arena is a biopharmaceutical company focused on discovering and developing novel, small molecule drugs. We are currently directing our activities and resources primarily on:

Stock Quote

Price

Change

High

View Details Stock Lookup

Date	Title and Summary
Toggle Summary 07 Nov '19	Arena Reports Third Quarter Financial Results with Continued Progress on Clinical Programs - Etrasimod initiation of the Phase 2 ADVISE trial in atopic dermatitis (AD) - Multiple first- or best-in-class drug candidates, skilled leadership team and liquidity position of approximately $1.2 billion SAN DIEGO , Nov. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. Earnings
Toggle Summary 06 Nov '19	Arena Pharmaceuticals Presented New Data Highlighting the Human Mass Balance and Metabolism Profile of Etrasimod at AAPS - In a Human Mass Balance study, etrasimod metabolism demonstrated no major metabolites - The overall results suggest low risk for drug-drug interactions SAN DIEGO , Nov. 6, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data evaluating the human mass balance, General

Date

Title and Summary

Nov '19

Arena Reports Third Quarter Financial Results with Continued Progress on Clinical Programs

- Etrasimod initiation of the Phase 2 ADVISE trial in atopic dermatitis (AD) - Multiple first- or best-in-class drug candidates, skilled leadership team and liquidity position of approximately $1.2 billion SAN DIEGO , Nov. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc.

Earnings

Nov '19

Arena Pharmaceuticals Presented New Data Highlighting the Human Mass Balance and Metabolism Profile of Etrasimod at AAPS

- In a Human Mass Balance study, etrasimod metabolism demonstrated no major metabolites - The overall results suggest low risk for drug-drug interactions SAN DIEGO , Nov. 6, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data evaluating the human mass balance,

General